Kiadis Pharma Announces Investor Events for September 2019
Company announces Notice of Results for the six months ended June 30, 2019
Amsterdam, The Netherlands, August 19, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, announces its investor events in September 2019.
Kiadis will be issuing its interim results for the six months ended June 30, 2019 at 7.00am CEST / 6.00am BST / 1.00am EDT on Tuesday, September 10, 2019.
Kiadis’ management will host a webcast and conference call for analysts on Tuesday, September 10, 2019 at 3.00pm CEST / 2.00pm BST / 9.00am EDT. A copy of the announcement will be made available on the Kiadis Pharma website and details of the webcast and conference call will be made available within the Investor section of the company website. The webcast will be recorded, and a replay will be made available.
In addition, members of the Kiadis management team will attend the following investor events in September:
Hot in Healthcare
September 19, 2019, Amsterdam, The Netherlands
Kiadis will be participating in one-on-one meetings with investors on 19 September.
KBC Annual Healthcare Conference
September 26, 2019, Brussels, Belgium
Kiadis will be participating in one-on-one meetings with investors on 26 September.
Maryann Cimino, Manager, Corporate Affairs
Tel: +1 (617) 710-7305
|Optimum Strategic Communications:|
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
About Kiadis Pharma
Founded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with late-stage blood cancers. With headquarters in Amsterdam, the Netherlands, and offices in the US and across Europe, Kiadis Pharma is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.